Florence Wong, MD is a Full Professor at the University of Toronto and staff Hepatologist at the Toronto General Hospital, Ontario, Canada. She received her medical degree from the University of Melbourne, Australia and completed her postgraduate training in Australia and in Toronto, Canada.

Apart from caring for a large population of patients with advanced liver cirrhosis, Dr. Wong has been active in research in the pathogenesis of portal hypertension, ascites formation, liver-kidney interactions, including the development of hepatorenal syndrome, and renal failure in cirrhosis for the past 30 years.

She has been the Secretary of the International Ascites Club, organizing two international meetings on the complications of ascites. She also held the position as the Chair of the Education Committee of the Canadian Association for the Study of the Liver. She has served as the Chair of the “Acute-on-Chronic Liver Failure Special Interest Group” of the American Association for the Study of the Liver, and organizer of the Single Topic Symposium of Acute-on-Chronic Liver Failure. Recently, she was the Deputy Editor of Liver Transplantation, and more recently, she has been selected to be a member of the Nomination Committee of the American Association for the Study of the Liver. She regularly speaks on topics related to advanced cirrhosis at academic meetings.

She has published widely on the topics related to ascites, and renal dysfunction in cirrhosis. She has more than 300 peer-reviewed publications as well as contributing regular reviews, book chapters and editorials on similar topics. She participated in the writing of the guidelines for the management of refractory ascites and for the management of acute-on- chronic liver failure for the American Association for the Study of the Liver. She is also a member of the writing committee for the treatment guidelines for acute on chronic liver failure for the American College of Gastroenterology. She has acted as consultant for the pharmaceutical and device industries for clinical studies on ascites and renal dysfunction in cirrhosis, especially on the use of terlipressin for hepatorenal syndrome and the use of an automated low-flow ascites (alfa) pump for ascites. Most recently, she has been responsible for putting together a landmark international document defining renal failure in cirrhosis.

She is the recipient of the Gold Medal from the Canadian Liver Foundation and the Canadian Association for the Study of the Liver for her contribution to academia in Hepatology. She is also the recipient of the 2023 Distinguished Achievement Award from the American Association for the Study of the Liver.